Mineralys Therapeutics, Inc. - MLYS STOCK NEWS

Mineralys Therapeutics (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focusing on developing medicines for hypertension, chronic kidney disease (CKD), and aldosterone-related disorders, has announced its plan to release second quarter 2024 financial results on Tuesday, August 13, 2024, after market close. The company will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the results. Interested parties can access the call via domestic (1-877-407-9127) or international (1-201-689-8574) phone numbers, or through a webcast link available on the company's Investor Relations webpage.

Mineralys Therapeutics (NASDAQ: MLYS) has appointed Dr. Alexander M. Gold to its Board of Directors, effective June 13, 2024. Dr. Gold, a cardiologist with over 20 years of experience, has a strong background in developing and commercializing new therapies. His previous roles include Chief Medical Officer at Sanifit-CSL and Senior Vice President at Portola Pharmaceuticals. Concurrently, Dr. Olivier Litzka has resigned from the Board to focus on his venture capital investments. Mineralys is currently advancing the late-stage clinical development of lorundrostat, aimed at treating hypertension and other cardiorenal metabolic disorders.

Mineralys Therapeutics (NASDAQ: MLYS), a clinical-stage biopharmaceutical company, will participate in the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL from June 10-13, 2024. The company's management will engage in a fireside chat on June 11, 2024, at 4:00 pm EDT. The discussion will be webcast live and accessible through the Investor Relations section on the Mineralys website, with a replay available for 90 days.

Mineralys Therapeutics, a clinical-stage biopharmaceutical company, reported its first quarter 2024 financial results and provided a corporate update. The company is focused on developing medicines targeting hypertension, chronic kidney disease, and other diseases related to dysregulated aldosterone. Their ongoing clinical trials for lorundrostat are expected to deliver topline data in Q4 2024 and 2H 2025. Mineralys also highlighted its strengthened balance sheet after completing a private placement financing in Q1 2024, providing them with sufficient funds until 2026.

Mineralys Therapeutics, a clinical-stage biopharmaceutical company, will participate in a fireside chat at the Bank of America Securities Health Care Conference. The company focuses on developing medicines for hypertension, chronic kidney disease, and diseases driven by dysregulated aldosterone. The event will take place in Las Vegas on May 14-16, 2024. Investors can access a live webcast and replay of the chat on the company's website.

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) will announce its first quarter 2024 financial results on May 9, 2024. The company focuses on developing medicines for hypertension, chronic kidney disease, and other diseases related to dysregulated aldosterone. The conference call will be hosted at 8:30 a.m. ET, offering dial-in and webcast options for participants.

Mineralys Therapeutics, Inc. (Nasdaq: MLYS) is progressing well with its pivotal trials for lorundrostat, focusing on treating hypertension and chronic kidney disease. Financially, the company reported a strong balance sheet with $239.0 million in cash, cash equivalents, and investments as of December 31, 2023. However, the company experienced significant increases in research and development expenses, leading to a net loss of $71.9 million for the year ended December 31, 2023.

Mineralys Therapeutics, Inc. (MLYS) to report financial results for Q4 and full year 2023 on March 21, 2024. The company focuses on developing medicines for hypertension and chronic kidney disease.

Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced a private placement financing (PIPE) with institutional accredited investors, raising approximately $120 million in gross proceeds. The financing involves selling 8.9 million shares of common stock at a price of $13.50 per share. The company plans to use the net proceeds to fund the research and development of lorundrostat, in addition to working capital and general corporate purposes.